Saad Z Usmani

Summary

Affiliation: University of Arkansas for Medical Sciences
Country: USA

Publications

  1. pmc Therapy-related myeloid malignancies in myeloma
    X Papanikolaou
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
    Mediterr J Hematol Infect Dis 3:e2011047. 2011
  2. pmc Second primary malignancies and myeloma therapy: fad or fact?
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
    Oncotarget 3:915-6. 2012
  3. pmc Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Blood 121:4753-7. 2013
  4. pmc Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 121:1819-23. 2013
  5. pmc Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols
    S Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Leukemia 26:2398-405. 2012
  6. pmc Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?
    S Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Leukemia 27:226-32. 2013
  7. pmc Thalidomide and its analogues in the treatment of Multiple Myeloma
    Tahir Latif
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W, Markham Street, Little Rock, AR, USA
    Exp Hematol Oncol 1:27. 2012
  8. pmc Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Haematologica 97:1761-7. 2012
  9. pmc Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 120:1597-600. 2012
  10. doi request reprint HSP90 inhibitors as therapy for multiple myeloma
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AZ 72205, USA
    Clin Lymphoma Myeloma Leuk 11:S77-81. 2011

Collaborators

  • Bart Barlogie
  • Frits van Rhee
  • Antje Hoering
  • Joshua Epstein
  • Yu Chen
  • Zihai Li
  • Ya Wei Qiang
  • Michele Cottler-Fox
  • John D Shaughnessy
  • Christoph J Heuck
  • Al Ola Abdallah
  • Sarah Waheed
  • Xenofon Papanikolaou
  • Donald Johann
  • Bo Hu
  • Jameel Muzaffar
  • Jackie Szymonifka
  • John Crowley
  • Nathan Petty
  • Elias Anaissie
  • Clyde Bailey
  • Tahir Latif
  • X Papanikolaou
  • Naveen S Kumar
  • Alejandro Restrepo
  • Shebli Atrash
  • Senu Apewokin
  • Monica Grazziutti
  • Muzaffar Jameel
  • Zainab Shahid
  • Lakshmikanth Katragadda
  • Alan Mitchell
  • Shmuel Yaccoby
  • Shiqiao Ye
  • Jason Keller
  • Wei Qiang
  • Adam Rosenthal
  • Sajjad Haider
  • Bart O Williams
  • Emily Hansen
  • Bijay Nair
  • Nabeel Chauhan
  • Andrea Moran
  • Yazan Alsayed
  • Rashid Khan

Detail Information

Publications17

  1. pmc Therapy-related myeloid malignancies in myeloma
    X Papanikolaou
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
    Mediterr J Hematol Infect Dis 3:e2011047. 2011
    ..Karyotypic abnormalities seem to be the main prognostic factor. In all cases the risk for therapy related myeloid malignancies drops sharply by 10 years after the treatment...
  2. pmc Second primary malignancies and myeloma therapy: fad or fact?
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
    Oncotarget 3:915-6. 2012
    ..It may well be that we are looking at the tip of the iceberg in the year 2012 and SPMs may emerge as an important long-term sequela with further follow-up...
  3. pmc Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Blood 121:4753-7. 2013
    ..Thus, treatment, host, and myeloma features could be linked to MDS development after therapy for this malignancy. This trial was registered at www.clinicaltrials.gov: TT3A: NCT00081939, TT3B: NCT00572169...
  4. pmc Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 121:1819-23. 2013
    ..This trial was registered at www.clinicaltrials.gov as #NCT00081939 and # NCT00572169...
  5. pmc Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols
    S Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Leukemia 26:2398-405. 2012
    ..Different treatment approaches building on these genomic differences may improve the grave outcome of patients with PPCL...
  6. pmc Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?
    S Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Leukemia 27:226-32. 2013
    ..Thus, a strategy using all myeloma-effective agents up-front seems effective at preventing, in progressively larger patient cohorts over time, the outgrowth of resistant tumor cells that account for ongoing relapses...
  7. pmc Thalidomide and its analogues in the treatment of Multiple Myeloma
    Tahir Latif
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W, Markham Street, Little Rock, AR, USA
    Exp Hematol Oncol 1:27. 2012
    ..This review discusses the available information regarding mechanisms of action, toxicity and clinical results on thalidomide, lenalidomide and pomalidomide in the therapy of multiple myeloma...
  8. pmc Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Haematologica 97:1761-7. 2012
    ..We evaluated the impact of this disease feature on patients' outcome in the context of novel agents...
  9. pmc Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 120:1597-600. 2012
    ..38; P = .09). These trials are registered at www.clinicaltrials.gov as NCT00573391 (TT2), NCT00081939 (TT3A), and NCT00572169 (TT3B)...
  10. doi request reprint HSP90 inhibitors as therapy for multiple myeloma
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AZ 72205, USA
    Clin Lymphoma Myeloma Leuk 11:S77-81. 2011
    ..This article serves as an overview of the pre-clinical data and clinical trial data on HSP90 inhibitors in multiple myeloma...
  11. doi request reprint Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia
    Saad Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences UAMS, Little Rock, AR 72205 7199, USA
    Clin Lymphoma Myeloma Leuk 11:139-42. 2011
    ..Based on these data and other series of autologous SCT experience, it may be feasible to employ this strategy upfront in transplant eligible WM patients when they require a therapeutic intervention for symptomatic disease...
  12. pmc The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    J Hematol Oncol 3:40. 2010
    ..We evaluated the in vitro anti-tumor activity and mechanism of action of PU-H71, a novel purine scaffold HSP90 inhibitor in human multiple myeloma cell lines...
  13. pmc Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma
    Xenofon Papanikolaou
    Myeloma Institute for Research and Therapy, Little Rock, AR, USA
    Haematologica 98:1147-53. 2013
    ..In conclusion, metronomic therapy is an effective late salvage treatment in relapsed/refractory multiple myeloma, with a high overall response rate and a favorable toxicity profile...
  14. pmc Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1
    Christoph J Heuck
    University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Clin Cancer Res 18:5499-506. 2012
    ....
  15. pmc Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma
    Bo Hu
    Myeloma Institute for Research and Therapy, Winthrop P Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America
    PLoS ONE 8:e74191. 2013
    ..These results provide a novel molecular mechanism critical to understanding the anabolic role of carfilzomib on myeloma-induced bone disease. ..
  16. ncbi request reprint Patterns of central nervous system involvement in relapsed and refractory multiple myeloma
    Al Ola Abdallah
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
    Clin Lymphoma Myeloma Leuk 14:211-4. 2014
    ..Invasion of CNS in MM is an extremely rare occurrence that is associated with advanced disease with poor prognosis...
  17. doi request reprint Waldenström's macroglobulinemia associated with serum amyloid A protein amyloidosis: pitfalls in diagnosis and successful treatment with melphalan-based autologous stem cell transplant
    Jameel Muzaffar
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Ark, USA
    Acta Haematol 130:146-9. 2013
    ....